Last 7.63 GBp
Change Today 0.00 / 0.00%
Volume 33.0K
EDEN On Other Exchanges
Symbol
Exchange
London
OTC US
As of 11:35 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

eden research plc (EDEN) Snapshot

Open
7.75 GBp
Previous Close
7.63 GBp
Day High
7.75 GBp
Day Low
7.63 GBp
52 Week High
09/24/13 - 17.25 GBp
52 Week Low
03/27/14 - 7.50 GBp
Market Cap
8.6M
Average Volume 10 Days
171.4K
EPS TTM
--
Shares Outstanding
113.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EDEN RESEARCH PLC (EDEN)

Related News

No related news articles were found.

eden research plc (EDEN) Related Businessweek News

No Related Businessweek News Found

eden research plc (EDEN) Details

Eden Research Plc engages in the development and marketing of intellectual property, primarily in the area of terpenes and other health-related projects in the United Kingdom. The company offers products in the areas of foliar disease control, soil pests, protected glass house crops, post harvest applications, and vascular disease control. It offers 3AEY, a terpene based fungicide; and develops various products for the control of botrytis, nematodes, powdery mildew, spider mites, and whiteflies, as well as vascular disease, such as esca, eutypa, and pierce's disease. The company was formerly known as Ximed Group plc and changed its name to Eden Research Plc as a result of the merger with Eden Research Inc in 2003. Eden Research Plc is headquartered in Witney, the United Kingdom.

5 Employees
Last Reported Date: 06/1/13

eden research plc (EDEN) Top Compensated Officers

Managing Director and Director
Total Annual Compensation: 40.0K GBP
Chief Financial Officer, Director and Member ...
Total Annual Compensation: 90.0K GBP
Executive Deputy Chairman
Total Annual Compensation: 72.0K GBP
Compensation as of Fiscal Year 2012.

eden research plc (EDEN) Key Developments

Eden Research PLC Announces Data Access Licence and Royalty Agreement with Desarrollo Agricola Y Minero S.A

Eden Research PLC announced that it has granted access to its EU regulatory data and dossiers to Desarrollo Agricola y Minero S.A. of Zaragoza, Spain. In 2013, Eden received approval for three active substances under the European Union Regulation No. 1107/2009 concerning the Placing of Plant Protection Products on the Market. This data, which was generated by Eden to register its own plant protection product 3AEY, is also of value to third parties as a basis to register their own products using one or more of the same active substances.

Eden Research PLC Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2013

Eden Research PLC reported unaudited consolidated earnings results for the six months ended June 30, 2013. For the period, the company reported group revenue of GBP 49,000 against GBP 8,000 a year ago. Operating loss was GBP 711,000 against GBP 959,000 a year ago. Loss on ordinary activities before taxation was GBP 713,000 against GBP 1,547,000 a year ago. Loss for the financial period was GBP 713,000 against GBP 1,547,000 a year ago. Loss per share - basic and diluted was 0.59 pence against 1.44 pence a year ago. Net cash used in operating activities was GBP 1,137,000 against GBP 1,627,000 a year ago. Capitalisation of development expenditure was GBP 24,000 against GBP 25,000 a year ago.

Eden Research plc Grants License to Neo-Pharma Innovations Limited to Develop Terpene-Based Head Lice Treatment for Commercial Sales

Eden Research plc announced that it has granted Neo-Pharma Innovations Limited a licence to develop its terpene-based head lice treatment for commercial sales. Under the terms of the agreement, NEO has a licence to Eden's intellectual property rights for the use of its patented, terpene based head lice treatment. The 20 year licence allows NEO to seek regulatory approvals for the product, as well as to manufacture and sell the treatment worldwide. It also allows them to develop products, using the same technology, that treat body lice, scabies and bed bugs. As part of the agreement, Eden has received an up-front licence fee and will also receive a milestone payment after the first regulatory approval of the product or following commencement of commercial sales, whichever is the earlier. Once commercial sales have begun, Eden will receive royalty payments in relation to these sales. Following the signing of the licence agreement NEO will proceed with product trials and will seek regulatory approvals and registrations for the product on a global basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EDEN:LN 7.63 GBp 0.00

EDEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EDEN.
View Industry Companies
 

Industry Analysis

EDEN

Industry Average

Valuation EDEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 121.5x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 122.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDEN RESEARCH PLC, please visit www.edenresearch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.